RT Journal Article
SR Electronic
T1 Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.04.21249959
DO 10.1101/2021.02.04.21249959
A1 Dravid, Ameet
A1 Kashiva, Reema
A1 Khan, Zafer
A1 Memon, Danish
A1 Kodre, Aparna
A1 Potdar, Prashant
A1 Mane, Milind
A1 Borse, Rakesh
A1 Pawar, Vishal
A1 Patil, Dattatraya
A1 Banerjee, Debashis
A1 Bhoite, Kailas
A1 Pharande, Reshma
A1 Kalyani, Suraj
A1 Raut, Prathamesh
A1 Bapte, Madhura
A1 Mehta, Anshul
A1 Reddy, M Sateesh
A1 Bhayani, Krushnadas
A1 Laxmi, S S
A1 Vishnu, P D
A1 Srivastava, Shipra
A1 Khandelwal, Shubham
A1 More, Sailee
A1 Shinde, Rohit
A1 Pawar, Mohit
A1 Harshe, Amol
A1 Kadam, Sagar
A1 Mahajan, Uma
A1 Joshi, Gaurav
A1 Mane, Dilip
YR 2021
UL http://medrxiv.org/content/early/2021/02/06/2021.02.04.21249959.abstract
AB Background Cytokine release syndrome (CRS) or cytokine storm is thought to be the cause of inflammatory lung damage, worsening pneumonia and death in patients with COVID-19. Steroids (Methylprednisolone or Dexamethasone) and Tocilizumab (TCZ), an interleukin-6 receptor antagonist, are approved for the treatment of CRS in India. The aim of this study was to evaluate the efficacy and safety of combination therapy of TCZ and steroids in COVID-19 associated CRS.Methods This retrospective cohort study was conducted at a tertiary level private hospital in Pune, India between 2nd April and 2nd November 2020. All patients administered TCZ and steroids for treatment of CRS were included. The primary endpoint was incidence of all-cause mortality. Secondary outcomes studied were need for mechanical ventilation and incidence of infectious complications. Baseline and time-dependent risk factors significantly associated with death were identified by Relative risk estimation.Results Out of 2831 admitted patients, 515 (24.3% females) were administered TCZ and steroids. Median age of the cohort was 57 (IQR: 46.5, 66) years. Almost 72 % patients had preexisting co-morbidities. Median time to TCZ administration since onset of symptoms was 9 days (IQR: 7, 11). 63% patients needed intensive care unit (ICU) admission. Mechanical ventilation was required in 242 (47%) patients. Of these, 44.2% (107/242) recovered and were weaned off the ventilator. There were 135 deaths (26.2%), while 380 patients (73.8%) had clinical improvement. Infectious complications like hospital acquired pneumonia, bloodstream bacterial and fungal infections were observed in 2.13 %, 2.13 % and 0.06 % patients respectively. Age ≥ 60 years (p=0.014), presence of co-morbidities like hypertension (p = 0.011), IL-6 ≥ 100 pg/ml (p = 0.002), D-dimer ≥ 1000 ng/ml (p < 0.0001), CT severity index ≥ 18 (p < 0.0001) and systemic complications like lung fibrosis (p = 0.019), cardiac arrhythmia (p < 0.0001), hypotension (p < 0.0001) and encephalopathy (p < 0.0001) were associated with increased risk of death.Conclusions Combination therapy of TCZ and Steroids is likely to be safe and effective in the management of COVID-19 associated cytokine release syndrome. Efficacy of this anti-inflammatory combination therapy needs to be validated in randomized controlled clinical trials.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicable. This a retrospective observational studyFunding StatementThis study did not receive any external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of database for clinical research was approved by the institutional review board (IRB) of Noble hospital and Research Centre, Pune, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified Data is freely available for fellow researchers at link given below https://figshare.com/s/cebdbaa0b8b84a59ae77 CRScytokine release syndromeTCZTocilizumabNHRCNoble hospital and Research CentreCOVID-19coronavirus disease 2019WHOWorld health organizationARDSacute respiratory distress syndromeIL-6interleukin-6RCTrandomized controlled trialsRT-PCRReverse-transcriptase polymerase chain reactionHRCTHigh resolution computerized tomography scanCRPC-reactive proteinIMVinvasive mechanical ventilationICMRIndian council of Medical researchIQRinter-quartile rangeHAP/VAPHospital or ventilator associated pneumoniaNRBMNon re-breathing maskNIVnoninvasive ventilationHFNOHigh flow nasal oxygenBIPAPBi-level positive airway pressureGBSGuillaine Barre syndromeSGOT/SGPTserum glutamate oxaloacetate/pyruvate transferaseAKIAcute kidney injuryCSFcerebrospinal fluidMRSAMethicillin resistant Staphylococcus aureusE. coliEscherichia coliICUIntensive care unitRRRelative riskCIConfidence intervalSOFASequential organ failure assessmentPEEPpositive end expiratory pressureBMIBody mass index